Entero Healthcare Solutions Limited announced its audited financial results for the quarter and year ended March 31, 2026. The Board approved the re-appointment of Independent Directors and the internal auditor, M/s Ernst & Young LLP. Additionally, the company is set to acquire the business of Vishal Surgicals and Vishal Surgicals & Medicals through a slump sale. The Board also confirmed the date for the 8th Annual General Meeting scheduled for August 19, 2026.
Annual Financial Performance Highlights
For the financial year ended March 31, 2026, Entero Healthcare reported consolidated revenue from operations of Rs. 65,912.12 million, compared to Rs. 50,957.80 million in the previous year. The company achieved a consolidated profit for the year of Rs. 1,458.40 million. On a standalone basis, revenue from operations stood at Rs. 3,482.41 million with a net profit of Rs. 268.75 million for the same period.
Strategic Acquisitions and Business Expansion
The company has announced the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals, both partnership firms. The acquisition will be executed via a slump sale through the subsidiary, Sai Pharma Distributors Private Limited. This strategic move aims to generate additional business and revenue for the company, with completion expected by December 31, 2026. The total consideration for the business acquisition is capped at Rs. 63 million for Vishal Surgicals and Rs. 29.1 million for Vishal Surgicals & Medicals, covering net assets and milestone-based payments.
Leadership and Governance Updates
The Board of Directors has approved the re-appointment of Mr. Sujesh Vasudevan, Mr. Rajesh Shashikant Dalal, and Ms. Sandhya Gadkari Sharma as Non-Executive Independent Directors for a second five-year term, effective from August 25, 2026, to August 24, 2031, pending shareholder approval. Furthermore, M/s Ernst & Young LLP has been re-appointed as the Internal Auditor for the 2026-27 financial year.
Employee Stock Option Plan
In accordance with the Entero Employee Stock Option Plan 2023, the company allotted 7,240 equity shares to eligible employees at an exercise price of Rs. 804 per share. Additionally, the Board noted the grant of 7,300 fresh stock options to employees, demonstrating the company’s commitment to incentivizing its workforce.
Upcoming Annual General Meeting
The company has scheduled its 8th Annual General Meeting for Wednesday, August 19, 2026, at 12:30 p.m. IST. The meeting will be conducted via Video Conferencing or Other Audio-Visual Means to facilitate shareholder participation.
Source: BSE
